This unique pathological change sheds light on the novel pathogenesis of DCM and affords promising pathways for disease-specific DCM treatment through either neutralising the specific PDE4D isoforms or disrupting the PDE4D3/9-SERCA2a association. This evidence concerns the gene PDE4D and familial dilated cardiomyopathy.